Development of a Simple Chromatographic Method for the Determination of Piracetam in Human Plasma and Its Pharmacokinetic Evaluation

 

 Buy Article Permissions and Reprints

Abstract

Objective:

The objective of study was to develop an accurate and reproducible HPLC method for determination of piracetam in human plasma and to evaluate pharmacokinetic parameters of 800 mg piracetam.

Methods:

A simple, rapid, accurate, precise and sensitive high pressure liquid chromatography method has been developed and subsequently validated for determination of piracetam. This study represents the results of a randomized, single-dose and single-period in 18 healthy male volunteers to assess pharmacokinetic parameters of 800 mg piracetam tablets. Various pharmacokinetic parameters were determined from plasma for piracetam and found to be in good agreement with previous reported values. The data was analyzed by using Kinetica^® version 4.4 according to non-compartment model of pharmacokinetic analysis and after comparison with previous studies, no significant differences were found in present study of tested product.

Results:

The major pharmacokinetic parameters for piracetam were as follows: t_1/2 was (4.40±0.179) h; T_max value was (2.33±0.105) h; C_max was (14.53±0.282) µg/mL; the AUC_0–∞ was (59.19±4.402) µg · h/mL. AUMC_0–∞ was (367.23±38.96) µg. (h)²/mL; Ke was (0.16±0.006) h; MRT was (5.80±0.227) h; V_d was (96.36±8.917 L).

Conclusions:

A rapid, accurate and precise high pressure liquid chromatography method was developed and validated before the study. It is concluded that this method is very useful for the analysis of pharmacokinetic parameters, in human plasma and assured the safety and efficacy of piracetam, can be effectively used in medical practice.

• References

• 1 Xianqin W, Jiayin Z, Renai X. Determination of piracetam in rat plasma by LC-MS/MS and its application to pharmacokinetics. Biomed Chromatogr 2010; 24: 1108-1112
  CrossrefPubMedGoogle Scholar
• 2 Anindita B, Khandelwal KR, Deepali VM. Analytical method development and validation for piracetam as bulk and in pharmaceutical formulation. Int J Pharm Tech Res 2010; 2: 201-204
  PubMedGoogle Scholar
• 3 Platt D, Horn J, Summa JD. On the efficacy of piracetam in geriatric patients with acute cerebral ischemia, a clinically controlled double-blind study. Arch Gerontol Geriatr 1993; 16: 149-164
  CrossrefPubMedGoogle Scholar
• 4 Moldavkin GM, Voronina TA, Neznamov GG. Participation of GABA benzodiazepine receptor complex in the anxiolytic effect of piracetam. Eksp Klin Farmakol 2006; 69: 7-9
  PubMedGoogle Scholar
• 5 Curticapean A, Imre S. New validated method for piracetam HPLC determination in human plasma. J Biochem Biophys Methods 2007; 69: 273-281
  CrossrefPubMedGoogle Scholar
• 6 Jadhav RT, Payal PH, Pratibha PR. Formulation and evaluation of bilayered tablet of Piracetam and Vinpocetine. J Chem Pharm Res 2011; 3: 423-431
  PubMedGoogle Scholar
• 7 Doheny MT, OConnell MH, Patsalos PN. A high-performance liquid-chromatographic microanalytical procedure for the rapid estimation of Piracetam in plasma or cerebrospinal fluid. J Pharm Pharmacol 1996; 48: 514-516
  CrossrefPubMedGoogle Scholar
• 8 Louchahi K, Tod M, Bonnardel P. Determination of piracetam in human plasma and urine by liquid chromatography. J Chromatogr B 1995; 663: 385-389
  CrossrefPubMedGoogle Scholar
• 9 Mascher H, Kikuta C. Rapid method for the sensitive determination of piracetam in plasma by high-performance liquid chromatography. J Pharm Biomed Anal 1989; 7: 913-916
  CrossrefPubMedGoogle Scholar
• 10 Rameis H, Hitzenberger G, Kutscher R. Pharmacokinetics of piracetam: a study on the bioavailability with special regard to renal and non-renal elimination. Int J Clin Pharmacol Ther 1994; 32: 458-465
  PubMedGoogle Scholar
• 11 Saletu B, Hitzenberger G. Double-blind, placebo-controlled, pharmacokinetic and -dynamic studies with 2 new formulations of piracetam (infusion and sirup) under hypoxia in man. Int J Clin Pharmacol Ther 1995; 33: 249-262
  PubMedGoogle Scholar
• 12 Tacconi MT, Wurtman RJ. Piracetam, physiological disposition and mechanism of action. Adv Neural 1986; 43: 675-685
  PubMedGoogle Scholar
• 13 Gouliaev AH, Senning A. Piracetam and other structurally related nootropics. Brain Res Rev 1994; 19: 180-222
  CrossrefPubMedGoogle Scholar
• 14 Calliauw L, Marchau M. Clinical trials of piracetam in disorders of consciousness due to head injury. Acta Anaesthesiol Belg 1975; 26: 51-60
  PubMedGoogle Scholar
• 15 Winblad B. Piracetam, a review of pharmacological properties and clinical uses. CNS Drug Reviews 2005; 11: 169-182
  PubMedGoogle Scholar
• 16 Brown P, Steiger MJ, Thompson PD. Effectiveness of piracetam in cortical myoclonus. Mov Disord 1993; 8: 63-68
  CrossrefPubMedGoogle Scholar
• 17 Baltes EL, Gobert JG. Availability and plasma clearance of piracetam in man. Farmaco 1977; 3: 84-91
  PubMedGoogle Scholar
• 18 Lamparczyk H, Kowalski P, Rajzer D. Determination of Piracetam in human plasma by capillary electrophoresis. J Chromatogr B 1997; 692: 438-487
  PubMedGoogle Scholar
• 19 Hsin-H Y, Yang YH, Ko JY. Rapid determination of piracetam in human plasma and cerebrospinal fluid by micellar electrokinetic chromatography with sample direct injection. J Chromatogr A 2006; 1120: 27-34
  CrossrefPubMedGoogle Scholar
• 20 Ikeda A, Shibasaki H, Tashiro K. Clinical Trial of Piracetam in Patients with Myoclonus: Nationwide Multiinstitution Study in Japan. Mov Disord 1996; 11: 691-700
  CrossrefPubMedGoogle Scholar
• 21 Fliser D, Bischoff I, Hanses A. Renal handling of drugs in the healthy elderly Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged. Eur J Clin Pharmacol 1999; 55: 205-211
  CrossrefPubMedGoogle Scholar